VEGFA and neoplasm: ERO1 inhibition, on the one hand, might impair VEGF, enhancing the trafficking of tumor-reactive T cells to the tumor, while on the other, it might lower PD-L1 expression in tumors, reducing the related immunosuppressive mechanism (Fig. 4C).